Accutane Risk Management Program Changes Held Up By Celgene Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Four patents relating to the STEPS risk management program for Thalomid are an “obstacle” to implementing an augmented isotretinoin program, FDA says. The agency’s Office of Chief Counsel is reviewing the issue.
You may also be interested in...
FDA Approves "Unprecedented" Risk Management Program For Accutane
Wholesalers, pharmacists, prescribers and patients will have added responsibility under the iPLEDGE program.
FDA Approves "Unprecedented" Risk Management Program For Accutane
Wholesalers, pharmacists, prescribers and patients will have added responsibility under the iPLEDGE program.
Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005
The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.